|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6022958A
(en)
|
1986-08-13 |
2000-02-08 |
Bayer Corporation |
cDNAs coding for members of the carcinoembryonic antigen family
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
GB8800078D0
(en)
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel antibodies
|
|
US5162504A
(en)
|
1988-06-03 |
1992-11-10 |
Cytogen Corporation |
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
HU212924B
(en)
|
1989-05-25 |
1996-12-30 |
Chiron Corp |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5955075A
(en)
|
1992-03-11 |
1999-09-21 |
Institute Of Virology, Slovak Academy Of Sciences |
Method of inhibiting tumor growth using antibodies to MN protein
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5472693A
(en)
|
1993-02-16 |
1995-12-05 |
The Dow Chemical Company |
Family of anti-carcinoembryonic antigen chimeric antibodies
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
|
US6824993B2
(en)
|
1995-06-06 |
2004-11-30 |
Human Genome Sciences, Inc. |
Antibodies that bind human prostate specific G-protein receptor HPRAJ70
|
|
JP2000511403A
(ja)
|
1996-03-20 |
2000-09-05 |
イムノメディクス，インコーポレイテッド |
抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用
|
|
US6150508A
(en)
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7011812B1
(en)
|
1996-05-03 |
2006-03-14 |
Immunomedics, Inc. |
Targeted combination immunotherapy of cancer and infectious diseases
|
|
SK150298A3
(en)
|
1996-05-04 |
1999-04-13 |
Zeneca Ltd |
Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6590088B1
(en)
|
1996-07-19 |
2003-07-08 |
Human Genome Sciences, Inc. |
CD33-like protein
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
|
US5989604A
(en)
|
1996-12-19 |
1999-11-23 |
Adore-A-Pet, Ltd. |
Xylitol-containing non-human foodstuff and method
|
|
US5942602A
(en)
|
1997-02-13 |
1999-08-24 |
Schering Aktiengessellschaft |
Growth factor receptor antibodies
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6458933B1
(en)
|
1998-05-20 |
2002-10-01 |
Immunomedics, Inc. |
Therapeutic using a bispecific antibody
|
|
CA2380783C
(en)
|
1999-07-29 |
2009-01-27 |
Yashwant Deo |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
US6716966B1
(en)
|
1999-08-18 |
2004-04-06 |
Altarex Corp. |
Therapeutic binding agents against MUC-1 antigen and methods for their use
|
|
US7147850B2
(en)
|
1999-08-18 |
2006-12-12 |
Altarex Medical Corp. |
Therapeutic binding agents against MUC-1 antigen and methods for their use
|
|
CN1427891A
(zh)
|
2000-02-25 |
2003-07-02 |
美国政府由(美国)卫生和福利部部长代表 |
具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法
|
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
|
EP1309627B1
(en)
|
2000-08-08 |
2009-09-30 |
Immunomedics, Inc. |
Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody
|
|
EP1578345A2
(en)
|
2001-03-29 |
2005-09-28 |
RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. |
Peptides and antibodies to muc 1 proteins
|
|
EP1383802A4
(en)
|
2001-03-30 |
2005-08-03 |
Univ California |
ANTI-MUC-1 SINGLE CHAIN ANTIBODY FOR TARGETING TUMORS
|
|
US7183388B2
(en)
|
2001-03-30 |
2007-02-27 |
The Regents Of The University Of California |
Anti-MUC-1 single chain antibodies for tumor targeting
|
|
EP2277542B1
(en)
|
2001-06-01 |
2014-04-16 |
Cornell Research Foundation Inc. |
Modified antibodies to prostrate-specific membrane antigen and uses thereof
|
|
DE60232244D1
(de)
|
2001-06-21 |
2009-06-18 |
Glycomimetics Inc |
Nachweis und behandlung von prostatakrebs
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
AR036833A1
(es)
|
2001-10-18 |
2004-10-06 |
Bayer Corp |
Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
AU2002351208A1
(en)
|
2001-12-03 |
2003-06-17 |
Abgenix, Inc. |
Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
|
|
BR0307216A
(pt)
|
2002-01-28 |
2005-12-20 |
Medarex Inc |
Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
|
|
DK3031910T3
(en)
|
2002-02-21 |
2017-10-23 |
Inst Virology |
MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
|
|
US20090162382A1
(en)
|
2002-03-01 |
2009-06-25 |
Bernett Matthew J |
Optimized ca9 antibodies and methods of using the same
|
|
KR101017732B1
(ko)
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-ｃｄ74 항체 및 그 이용방법
|
|
CN1646160A
(zh)
|
2002-03-13 |
2005-07-27 |
拜奥根Idec马萨诸塞公司 |
抗αvβ6抗体
|
|
US7435797B2
(en)
|
2002-04-10 |
2008-10-14 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
SE0202110D0
(sv)
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
|
US20090252738A1
(en)
|
2002-08-23 |
2009-10-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
CN101972478B
(zh)
|
2002-10-08 |
2012-10-31 |
免疫医疗公司 |
抗体治疗
|
|
BR0316101A
(pt)
|
2002-11-07 |
2005-09-27 |
Immunogen Inc |
Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
|
|
US7438907B2
(en)
|
2002-11-15 |
2008-10-21 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
|
EP1587837B1
(en)
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
CN1767860A
(zh)
|
2003-01-31 |
2006-05-03 |
免疫医疗公司 |
施用治疗和诊断剂的方法和组合物
|
|
WO2004072117A2
(en)
|
2003-02-13 |
2004-08-26 |
Pharmacia Corporation |
Antibodies to c-met for the treatment of cancers
|
|
MXPA05013181A
(es)
|
2003-06-06 |
2006-06-23 |
Genentech Inc |
Metodos y composiciones para modular hgf/met.
|
|
CN102558352A
(zh)
|
2003-06-27 |
2012-07-11 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
SE0301998D0
(sv)
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
US20050233960A1
(en)
|
2003-12-11 |
2005-10-20 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
|
US20060035907A1
(en)
|
2004-02-23 |
2006-02-16 |
Christensen James G |
Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors
|
|
CA2566950A1
(en)
|
2004-07-02 |
2006-01-12 |
Wilex Ag |
Improved adjuvant therapy of g250-expressing tumors
|
|
KR20140032004A
(ko)
|
2004-07-22 |
2014-03-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
EP1773885B1
(en)
|
2004-08-05 |
2010-04-21 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
|
US7491390B2
(en)
|
2004-10-15 |
2009-02-17 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
PT1817345E
(pt)
|
2004-11-09 |
2009-08-21 |
Philogen Spa |
Anticorpos contra a tenascina c
|
|
AU2005322410B2
(en)
|
2004-11-30 |
2011-11-10 |
Amgen Fremont Inc. |
Antibodies directed to GPNMB and uses thereof
|
|
BRPI0607796A2
(pt)
|
2005-02-18 |
2009-06-13 |
Medarex Inc |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
WO2006104911A2
(en)
|
2005-03-25 |
2006-10-05 |
Genentech, Inc. |
Methods and compositions for modulating hyperstabilized c-met
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
US20090304721A1
(en)
|
2005-09-07 |
2009-12-10 |
Medlmmune, Inc |
Toxin conjugated eph receptor antibodies
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
EP2004693B1
(en)
|
2006-03-30 |
2012-06-06 |
Novartis AG |
Compositions and methods of use for antibodies of c-met
|
|
CA2647671A1
(en)
|
2006-03-31 |
2007-11-01 |
Massachusetts Institute Of Technology |
Treatment of tumors expressing mutant egf receptors
|
|
KR101496433B1
(ko)
|
2006-06-07 |
2015-02-26 |
바이오얼라이언스 씨.브이. |
암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
|
|
TW200815474A
(en)
|
2006-08-03 |
2008-04-01 |
Astrazeneca Ab |
Antibodies alphaVbeta6 and uses thereof
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
WO2008073598A2
(en)
|
2006-10-31 |
2008-06-19 |
Immunogen, Inc. |
Methods for improving antibody production
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
RU2476441C2
(ru)
|
2007-10-19 |
2013-02-27 |
Сиэтл Дженетикс, Инк. |
Cd19-связывающие средства и их применение
|
|
EP2219668A1
(en)
|
2007-11-02 |
2010-08-25 |
Wilex AG |
Binding epitopes for g250 antibody
|
|
KR101672271B1
(ko)
|
2007-12-18 |
2016-11-03 |
바이오얼라이언스 씨.브이. |
암세포에서 발현된 ｃｄ-43 및 ｃｅａ 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법
|
|
EP2231183A2
(en)
|
2007-12-21 |
2010-09-29 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
|
ES2526433T3
(es)
|
2007-12-26 |
2015-01-12 |
Biotest Ag |
Inmunoconjugados dirigidos a CD138 y usos de los mismos
|
|
CA2710453C
(en)
|
2007-12-26 |
2019-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
JP6049163B2
(ja)
|
2008-07-21 |
2016-12-21 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
改善された治療上の特徴のための抗体の構造変異体
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
BRPI0921433A2
(pt)
|
2008-10-31 |
2017-06-06 |
Abbott Biotherapeutics Corp |
uso de anticorpos anti-cs1 para o tratamento de linfomas raros
|
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
NZ613647A
(en)
|
2009-05-06 |
2015-02-27 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
|
CN102421798A
(zh)
|
2009-05-07 |
2012-04-18 |
诺瓦提斯公司 |
与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
EP3009455A1
(en)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Class i anti-cea antibodies and uses thereof
|
|
US20110028129A1
(en)
|
2009-10-13 |
2011-02-03 |
Hutchison James W |
Proximity Triggered Profile-Based Wireless Matching
|
|
KR101671378B1
(ko)
|
2009-10-30 |
2016-11-01 |
삼성전자 주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
|
|
KR101748707B1
(ko)
|
2009-11-27 |
2017-06-20 |
삼성전자주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
|
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
AU2013328625B2
(en)
*
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
SG11201601763SA
(en)
|
2013-09-20 |
2016-04-28 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
GB201506405D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
TN2017000440A1
(en)
|
2015-04-17 |
2019-04-12 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
GB201507827D0
(en)
*
|
2015-05-07 |
2015-06-17 |
Adc Therapeutics Sarl |
Diagnostic test
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
CA2988115A1
(en)
|
2015-06-03 |
2016-12-08 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
GB201513607D0
(en)
*
|
2015-07-31 |
2015-09-16 |
Feingold Jay M |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN108473587A
(zh)
|
2016-01-25 |
2018-08-31 |
辉瑞公司 |
用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合
|
|
CN109641051A
(zh)
*
|
2016-06-17 |
2019-04-16 |
美真达治疗公司 |
用于耗尽细胞的组合物和方法
|
|
CN109862919A
(zh)
*
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
AU2018253950A1
(en)
*
|
2017-04-20 |
2019-09-19 |
Adc Therapeutics Sa |
Combination therapy with an anti-CD25 antibody-drug conjugate
|
|
BR112019026498A2
(pt)
*
|
2017-06-14 |
2020-07-14 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd25
|